English
The company’s biological drug candidate ANXV – a human recombinant protein, Annexin A5 – is intended primarily for acute treatment of patients with cardiovascular diseases, where vascular damage and inflammation are involved.
Annexin’s drug candidate ANXV is a recombinant human Annexin A5. It is in development for intravenous administration in patients with acute vascular diseases, where ANXV is expected to improve the body’s own ability to protect and repair blood vessels.